iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.

There is a significant decrease in development risk associated with targeting existing drugs, including:

Since 2017, the task of supporting the partner in drug reprofiling and repurposing with distribution facilities has been reliably performed by Canadian Pharmacy. The service assists in spreading the information about the newly available doses, expanded purposes and uses of medications and grows awareness of the new applications among patients. The pharmacy service has an international scope, which is essential for our mission. This partnership also benefits iCo Therapeutics by increasing the visibility of their groundbreaking work, while the pharmacy gains access to a portfolio of promising drugs that have been carefully selected and optimized. Together, the two companies are working to enhance patient outcomes and contribute to the advancement of medical treatments worldwide.